Burkina Faso vs IDA blend: Access to anti-retroviral drugs, female
Burkina Faso
98.0%
in 2024
IDA blend
88.4%
in 2024
Burkina Faso rank
1st
IDA blend rank
3rd
Access to anti-retroviral drugs, female over time
- Burkina Faso
- IDA blend
How they compare
Burkina Faso currently reports 98.0% against 88.4% in IDA blend, a difference of 9.6%.
That makes Burkina Faso's figure about 1.1 times IDA blend's.
The two have swapped places 1 time across 25 shared years of data; in 2000 it was IDA blend ahead.
Burkina Faso ranks 1st and IDA blend ranks 3rd of 141 countries.
Burkina Faso has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Burkina Faso | IDA blend | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 10.1% | 5.2% | 4.9% | Burkina Faso |
| 2010s | 67.6% | 51.6% | 16.0% | Burkina Faso |
| 2020s | 91.8% | 83.0% | 8.8% | Burkina Faso |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Burkina Faso or IDA blend?
- Burkina Faso, at 98.0% against 88.4% in IDA blend as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Burkina Faso and IDA blend?
- 9.6%, with Burkina Faso ahead.
- How many years of comparable data are there for Burkina Faso and IDA blend?
- 25 years are reported by both, from 2000 to 2024.
- How do Burkina Faso and IDA blend rank globally for access to anti-retroviral drugs, female?
- Burkina Faso ranks 1st and IDA blend ranks 3rd of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.